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Abstract 
MicroRNAs (miRNAs) are small RNAs that
bind to mRNAs and regulate gene expression.
MyoMirs  are  miRNAs  implicated  in  cardio-
genesis.  Some  MyoMirs  have  been  found
deregulated in hearts from patients with left
ventricular hypertrophy (LVH). DNA variants
at these miRNAs could contribute to the risk
of  developing  hypertrophic  cardiomyopathy
(HCM). To test this hypothesis we used single
strand  conformation  analysis  and  direct
sequencing to search for DNA variants in the
mir-208a, miR-208b, miR-133a-1, miR-133a-2,
miR-133b,  miR-1-1,  and  miR-1-2  genes  in
patients with HCM (n=245), LVH secondary
to  hypertension  (n=120),  and  healthy  con-
trols  (n=250).  We  found  several  nucleotide
variants. Genotyping of patients and healthy
controls  showed  significantly  associations
between  a  133a-1  polymorphism  and  HCM
and a 133b polymorphism and hypertensive-
LVH. We concluded that rare variants in these
mature miRNAs would be rarely found among
HCM patients, but miR-133a-1 and 133b poly-
morphisms  could  contribute  to  the  risk  of
developing cardiac hypertrophy. 
Introduction
Micro RNAs (miRNAs) are small non-coding
RNAs that negatively regulate gene expression
at the posttranscriptional level. By base pairing
to  the  3’  untranslated  regions  (3’UTRs)  of
messenger  RNAs  (mRNAs),  miRNAs  repress
the  expression  of  many  genes  and  regulate
physiological processes such as cell differenti-
ation,  growth,  proliferation,  and  apoptosis.1
Several miRNAs play an important role in myo-
genesis and heart development and function,
and are designated as MyoMIRS. 
The biogenesis of miRNAs involves several
steps: first a pri-miRNA is synthesized by the
action of RNA polymerase II; in a second step,
the  pri-miRNA  is  processed  by  the  enzyme
Drosha to give an approximately 90 nucleotides
long  pre-miRNA.2 Pre-miRNAs  form  several
stem-loop secondary structures that are neces-
sary for a correct cleavage that renders a double
stranded miRNA, that is then processed to the
single-strand mature miRNA and incorporated
into the RNA induced silencing complex (RISC;
a  ribonucleoprotein  complex  that  regulates
mRNA  expression).3 The  genes  encoding
miRNAs  are  mono-  or  polycystronic  (i.e. the
miR-1-1/miR-133a-2  and  miR-1-2/miR-133a-1
clusters),  and  either  inserted  in  introns  (i.e.
miR208a and 208b) or in intergenic regions. A
genome-wide  survey  of  human  single
nucleotide  polymorphisms  (SNPs)  suggested
that <1% of the miRNAs have SNPs in their
mature  sequences,  while  ~10%  of  the  pre-
miRNA sequences are polymorphic.4 These pre-
miRNA polymorphisms could affect the process-
ing of miRNAs, being thus of relevance for the
susceptibility to diseases.5
Left  ventricular  hypertrophy  (LVH)  is  a
pathological response to some cardiovascular
diseases, such as valvular disease, ischemic
heart disease, and hypertension. Hypertrophic
cardiomyopathy (HCM) is the left ventricular
wall thickening in the absence of cardiac or
systemic  disease  capable  of  producing  the
hypertrophy.  HCM  is  frequently  familial  and
transmitted  as  an  autosomal-dominant  trait,
and  the  genes  primarily  involved  in  HCM
encode proteins of the sarcomere.6However, in
all  the  large  reported  cohorts  a  significant
number of patients did not have sarcomeric
mutations, suggesting that other not yet iden-
tified genes could be implicated in this dis-
ease.7 Recent reports have elucidated the role
of several miRNAs in cardiac hypertrophy.8 The
overexpression of some miRNAs (i.e.miR-208)
has been linked to hypertrophy in mice.9 In
contrast, in vitro overexpression of miR-133
and miR-1 inhibited cardiac hypertrophy, while
suppression of the miR-133 pathway induced
hypertrophy.10 These  miRNAs  enhanced
myoblast  proliferation  by  repressing  the
expression of serum response factor, an essen-
tial activator of myogenesis, and several genes
that  have  been  implicated  in  cardiogenesis
and hypertrophy are targets of miR-133.8,11 The
expression of miR-133 has been assessed in
murine  models  of  cardiac  hypertrophy.  The
transverse aortic archconstricted mice devel-
oped  pressure  overload  and  cardiac  myocyte
hypertrophy and showed a reduced expression
of miR-133, indicating that this miRNA family
could be involved in the development of cardiac
hypertrophy in response to hypertension.11
Based on the role of several miRNAs in the
pathogenesis  of  HCM  and  the  association
between miRNA gene variants and some dis-
eases, we hypothesised that myoMIR variants
could also act as HCM-risk factors. To test this
hypothesis  we  defined  the  DNA  variation  at
several miRNAs in a group of HCM-patients
and healthy controls.
Materials and Methods
Patients and controls
The study was based on a total of 245 HCM
patients  recruited  through  the  Cardiology
Department of HUCA.
The inclusion criteria and main character-
istics of these patients had been previously
reported.12,13 HCM  was  diagnosed  based  on
the echocardiographic finding of a left ven-
tricular septum >15 mm in the absence of any
other disease that could explain the hypertro-
phy. All the HCM patients were screened for
mutations  in  the  most  frequently  mutated
sarcomeric genes: beta myosin heavy chain
(MYH7), cardiac troponin T (TNNT2), alpha-
tropomyosin  (TPM1),  cardiac  troponin  I
(TNNI3),  and  myosin  binding  protein  C3
(MYBPC3).12 We  also  studied  120  patients
with LVH secondary to hypertension. The con-
trol group consisted on 250 healthy individu-
als  who  did  not  have  symptoms  of  cardiac
hypertrophy. However, they were not echocar-
diographically examined to exclude the exis-
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tence of asymptomatic LVH. Patients and con-
trols were Caucasians from the same region
(Asturias, Northern Spain, total population 1
million), and gave their informed consent to
participate  in  the  study,  approved  by  the
Ethical  Committee  of  Hospital  Central
Asturias. 
Identification of myoMIR variants 
All the experimental procedures are avail-
able upon request to the corresponding author.
Genomic  DNA  was  obtained  from  10  mL  of
blood, and 350 to 450 nucleotides of the mir-
208a, -208b, -133a-1, -133a-2, -133b, -1-1, and -
1-2  genes  were  polymerase  chain  reaction
(PCR)-amplified. To search for sequence vari-
ants, the PCR fragments were amplified from
all the HCM patients and analysed through sin-
gle strand conformation analysis (SSCA). PCR-
fragments from individuals who showed het-
erogeneous  SSCA  patterns  were  sequenced
using  BigDye  chemistry  in  an  automated
ABI3130 capillary system (Applied Biosystems,
Foster City, CA, USA) to identify the nucleotide
changes. The nucleotide variants were num-
bered  according  to  the  mature  miRNA
sequences,  with  -1  and  +1  as  the  first  5’
upstream  and  3’  downstream  nucleotide,
respectively. 
Genotyping of myoMIR variants
All the patients and controls were genotyped
for the myoMIR variants based on their SSCA
patterns (208a, 208b, 133a2) or through diges-
tion  with  a  restriction  enzyme  (PCR-RFLP;
133b and 133a1) as reported.14 To validate the
accuracy of these methods we confirmed the
genotype from several individuals by sequenc-
ing the PCR-fragments (Figure 1). 
Statistical analysis
Allele  and  genotype  frequencies  in  patients
and  controls  were  compared  through  a  chi-
squared test. Odds ratios (OR) with 95% confi-
dence intervals (CI) were obtained to calculate
the relative risk associated with the genotypes.
Because sarcomeric mutations can explain the
development of HCM in some patients, in order to
maximize  the  chance  of  detecting  any  effect
MyoMIR  polymorphisms  on  HCM-risk  we  also
compared  the  allele/genotype  frequencies
between patients with and without sarcomeric
mutations and controls. The chi-squared was also
used  to  analyse  the  deviation  from  the
Hardy–Weinberg equilibrium of the genotype fre-
quencies. All statistical analyses were performed
with the SPSS statistical package (v.11.0).
Results
Table 1 summarizes the main characteris-
tics of patients and controls. SSCA of the 10
myoMIRs in the HCM patients showed hetero-
geneous electrophoretic patterns for the PCR
fragments of 208a, 208b, 133a-1, 133a-2, and
133b. A total of seven nucleotide changes were
identified,  and  two  were  new  changes  (no
reported  as  polymorphisms  in  the  ensembl
database; www.ensembl.org). Allele and geno-
type frequencies for these variants in patients
and controls are summarised in Table 2.
We  found  two  nucleotide  variants  in  the
miR-133a-1 and 133b sequences. Carriers of
the miR-133a-1 +85A were significantly more
frequent in HCM patients without sarcomeric
mutations  (12%)  compared  to  controls  (5%;
P=0.02,  OR=2.30,  95%=1.13-4.67),  HCM
patients with sarcomeric mutations, and LVH-
hypertensives. Carriers of the -90A-deletion in
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Table 1. Main characteristics of the patients with HCM and LVH secondary to hyper-
tension.
HCM (n=245) Hypertensive LVH (n=120)
Mean age at diagnosis (years) 45±13 58±17
Rang 18-75 35-75
Male 144 (59%) 71(59%)
Family history
(HCM or sudden death) 105 (43%) -
Mean BMI
Male 27±3 28±4
Female 26±4 28±5
Mean IVS (mm) 20±5 15±5
Mean PWT (mm) 13±5 10±6
Mean LVWT 34±6 26±6
Dyspnea 168 (69%) 36 (30%)
NYHA index
Class I-II 120 (48%) 28 (23%)
Class III-IV 48 (20%) 8 (7%)
Angina 96 (39%) 19 (16%)
Syncope 48 (20%) 7 (6%)
Atrial fibrillation 47 (19%) 18 (15%)
Arrhythmia (Holter monitoring) 55 (22%) 20 (17%)
LVOT >30 mm Hg 72 (29%) 32 (27%)
Sarcomeric mutations 40 (16%) -
MYH7 12 (5%) -
MYBPC3 22 (9%) -
TNNT2 4 (2%) -
TPM1 1 (<1%) -
TNNI3 1 (>1%) -
HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; IVS, interventricular septum; PWT, posterior wall thickness; LVWT, left
ventricular wall thickness; NYHA, New York Heart Association functional class; LVOT, left ventricular outflow tract gradient.
Figure 1. Single strand conformation analysis (SSCA) and polymerase chain reaction
(PCR)-RFLP patterns and sequence for the three 133b ins/del A genotypes.
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miR-133b  were  significantly  more  frequent
among the LVH-hypertensives (17%) compared
to  controls  (8%;  P=0.03,  OR=1.99,  95%
CI=1.06-3.76),  and  HCM  patients  (Table  2).
Moreover,  two  LVH-hypertensives  were  delA
homozygotes compared to none in the control
and HCM groups. This suggested that the -90
del A could be a risk factor for LVH secondary to
hypertension.  An  online  analysis  (MFold,
http://mfold.rna.albany.edu)  showed  that  the
miR-133a-1  and  miR-133b  polymorphisms
altered the secondary structure of the two pri-
miRNAs (Figure 2). 
We found three previously reported 133a-2
SNPs:  -191  G/A  (SNP  reference  number
rs45547937),  171G/A  (rs13040566),  and  -88
G/A (rs13040413). Sequencing of several cases
with different SSCA patterns showed three dif-
ferent  allele  combinations:  -191AA/-171AA/-
88AA,  -191GG/-171GG/-88GG,  and  -191AG/-
171AG/-88AG.  This  suggested  that  the  three
133a-2 SNPs were in complete linkage disequi-
librium, defining two haplotypes: -191A/-171A/-
88A and -191G/-171G/-88G. No significant dif-
ference was found between patients and con-
trols for these polymorphisms.
We  found  a  rare  miR-208a  variant  (-175
C>A)  in  one  HCM  patient,  a  66  years  old
female with a septum of 26 mm and no muta-
tions  in  the  sarcomeric  genes.  No  relatives
were available for the genetic study to deter-
mine whether this variant segregated with the
disease.
Discussion
The  variation  at  the  mature  miRNA
sequences could affect the binding of their tar-
get mRNAs (the seed region) and affect the
capacity to regulate gene expression. Naturally
occurring  changes  in  these  critical  miRNA
nucleotides  are  very  rare.  In  a  search  for
nucleotide  variants  in  227  human  miRNAs,
Duan et al. only found one SNP in the mature
miR-125a.5 Nucleotide  changes  in  mature
miRNAs are commonly found in tumor tissues
as  acquired  mutations  associated  with  the
development of several cancer types.15-17 None
of the myoMIR variants found in our study was
in the mature miRNA sequences. We thus con-
cluded that nucleotide changes in these criti-
cal regions would not contribute to the risk of
developing cardiac hypertrophy. 
We found a significant association between
common  variants  in  the  133a-1  and  133b
miRNA  genes  and  HCM  without  sarcomeric
mutations and LVH secondary to hypertension,
respectively.  Nucleotide  variants  in  miRNA
genes could disrupt the normal RNA secondary
structure and could have an effect on disease
risk through the processing and expression of
the pre-miRNA and mature miRNA.16 All the
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Table 2. Genotype and allele frequencies for the myoMIR polymorphisms.
HCM HCM LVH-
No mutation Mutation Hypertensives Controls
(n=205) (n=40) (n=120) (n=250)
miR-133a-1*:
+85 A/C
AA 3 (2%) 00 0
AC 20 (10%) 2 (5%) 4 (3%) 13 (5%)
CC 182 (88%) 38 (95%) 116 (97%) 237 (95%)
A 0.06 0.03 0.02 0.03
C 0.94 0.97 0.98 0.97
miR-133a-2: 
-191G/A -171G/A -88G/A 
(rs45547937/rs13040566/rs13040413)
AA/AA/AA 8 (4%) 2 (5%) 7 (6%) 10 (4%)
AG/AG/AG 65 (32%) 12 (30%) 41 (34%) 82 (33%)
GG/GG/GG 131 (64%) 26 (65%) 72 (60%) 158 (63%)
AAA 0.20 0.20 0.23 0.18
GGG 0.80 0.80 0.77 0.82
miR-133b**: 
-90 ins/delA
ins/ins 187 (91%) 37 (92%) 99 (83%) 230 (92%)
ins/del 18 (9%) 3 (8%) 18 (15%) 19 (8%)
del/del 00 3 (2%) 1
insA 0.96 0.96 0.90 0.95
delA 0.04 0.04 0.10 0.05
miR-208 a:
-175 C/A (rs28730766)
CC 204 (99%) 40 120 250
CA 1 (1%) 00 0
AA 00 0 0
miR-208 b: 
+95 C/T (rs45489294)
CC 200 (98%) 38 (95%) 116 (97%) 244 (98%)
CT 5 (2%) 2 (5%) 4 (3%) 6 (2%)
TT 00 0 0
C 0.99 0.97 0.98 0.90
T 0.01 0.03 0.02 0.10
HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVH, left ventricular hypertrophy. *P=0.02, OR=2.30 (1.13-4.67), AA+AC vs. CC, HCM
no mutation vs. controls, P= 0.006, OR= 2.53 (1.28-5.01) A vs. C, HCM no mutation vs. controls; **P=0.03, OR=1.99 (1.06-3.76, del/del +
ins/del vs. ins/ins, LVH vs. controls, P=0.01, OR= 2.11 (1.18-3.78) ins vs. del, LVH vs. controls.
Figure 2. Secondary structure of the 133A-1 and 133b pri-miRNAs containing the two
alleles.  The 5’ and 3’ ends of the pre-miRNAs are also indicated.
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myoMIR variants found in our study were out
of the pre-miRNA sequence and a direct effect
on  the  secondary  structure  of  the  double-
stranded stem of the pre-miRNA hairpin could
thus  be  excluded.  Although  the  133a-1  and
133b  nucleotide  polymorphisms  would  alter
the  pri-miRNAs  secondary  structure,  struc-
turally relevant changes in pri-miRNAs would
not affect processing.18
These nucleotide changes could modify the
binding  of  transcription  factors  (TFs)  and
enhancers,  regulating  miRNA  gene  expres-
sion. Mice lacking the myocyte enhancer fac-
tor-2 (MEF2) exhibited a down-regulation of
the  miR-1-1/miR-133a-2  and  miR-1-2/miR-
133a-1  transcripts,  and  a  MEF2  enhancer
sequence located between miR-1-1 and 133a-2
has  been  identified.10 The  mutation  of  this
MEF2  enhancer  abolished  miR-1-1/133a-2
expression on cardiac and skeletal muscle cells
of transgenic mice. A MEF2-like site was also
identified in the region between miR-1-1 and
miR-133a-2,  suggesting  that  the  two  miR-
1/miR-133a clusters contain similar regulatory
elements.19 We searched for putative TFs bind-
ing sites in the polymorphic sites found in our
study.  According  to  the  TFSEARCH  database
(http://mbs.cbrc.jp/research/db/TFSEARCH.htm
l),  the  133a-1  SNP  would  not  create/destroy
binding sites for known TFs. However, the -90
ins/del A in 133b affected a binding site for TFs
of the GATA family, that have been implicated
in cardiogenesis and cardiac hypertrophy.20,21
The -90 del A should destroy a binding site for
these TFs, and could thus reduce the expres-
sion of miR-133b, that in turn could have a pro-
hypertrophic  effect.  Functional  studies  are
necessary to confirm this putative effect of the
133b ins/del on gene expression.
The absence of a significant effect of these
miRNA  variants  on  HCM  with  sarcomeric
mutations likely reflects the fact that in these
patients  the  disease  was  caused  by  these
mutations.  However,  we  cannot  exclude  an
effect of these polymorphisms as modifiers of
disease  severity  and  adverse  events  among
HCM patients with sarcomeric mutations. The
higher  frequency  of  the  133b  polymorphism
among  the  LVH  hypertensives  could  be
explained by a role of this miRNA in the regu-
lation of physiological pathways that lead to
the development of LVH in response to hyper-
tension.22 Alternativelly,  this  polymorphism
could be related with the risk of developing
hypertension itself. A comparison between -90
delA frequencies in large cohorts of hyperten-
sives vs. normotensives should be necessary to
clarify this.
We are well aware that our work has several
limitations.  First,  SSCA  is  an  indirect  tech-
nique  for  detecting  nucleotide  changes  in
PCR-fragments.  Although  the  rate  for  false
negatives  is  very  low  (<5%)  we  can  not
exclude that some nucleotide variants in the
myoMIRs  were  not  identified  in  our  study.
Second, the association of the genotypes with
the risk of cardiac hypertrophy was based on a
limited number of patients and from a single
population. The replication of our study with
larger series of patients/controls and from dif-
ferent  populations  is  necessary  to  confirm  /
refute our results. In addition, functional stud-
ies should be necessary to determine the effect
of the nucleotide variants on miRNAs matura-
tion and expression. 
Conclusions
We  reported  nucleotide  variants  in  the
sequences  of  miR-1,  133,  and  208  genes.  A
miR-133a-1  SNP  could  be  a  risk  factor  for
HCM,  while  a  miR-133b  polymorphism  was
associated with cardiac hypertrophy secondary
to hypertension. To our knowledge, this is the
first  report  that  described  the  association
between microRNA gene variants and cardiac
hypertrophy. 
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